- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Larotrectinib Yields Impressive Responses Across All Age Groups and Tumor Types Harboring TRK Fusion Mutations
June 4th 2017, 1:16am
Three out of 4 patients representing a range of TRK fusion–positive solid tumors responded to the novel pan-TRK inhibitor larotrectinib (LOXO-101) and remain on treatment, setting the stage for the well-tolerated oral agent to become a standard of care for adults and children with any advanced tumor harboring this mutation.
Abemaciclib Extends PFS in Phase III Breast Cancer Trial
June 4th 2017, 12:21am
Adding the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression or death by 45% versus fulvestrant alone in pretreated patients with HR+/HER2-negative breast cancer, according to findings presented at the 2017 ASCO Annual Meeting.
Pembrolizumab/Chemo PFS Benefit in NSCLC Sustained With Longer Follow-Up
June 3rd 2017, 11:44pm
The frontline combination of pembrolizumab, pemetrexed, and carboplatin reduced the risk of progression or death by 50% and nearly doubled objective response rates compared with chemotherapy alone for patients with advanced non-squamous NSCLC.
Novel Sequencing Approach Detects Circulating Tumor DNA in 89% of Patients with Advanced Cancer
June 3rd 2017, 11:21pm
A new, high-intensity genomic sequencing approach for circulating tumor DNA uncovered at least 1 genetic change in both the tumor DNA and the blood of 89% of patients, demonstrating a high rate of concordance between 2 approaches for detecting molecular aberrations, according to a study presented at the 2017 ASCO Annual Meeting.
Abiraterone Studies Hailed as Practice-Changing in Newly Diagnosed Metastatic Prostate Cancer
June 3rd 2017, 9:56pm
Earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by nearly 40% for men with high-risk advanced or metastatic prostate cancer who were newly diagnosed or had not yet received hormone therapy in findings from 2 clinical trials presented at the 2017 ASCO Annual Meeting.
Pregnancy Does Not Increase Recurrence Risk of Early-Stage, ER-Positive Breast Cancer
June 3rd 2017, 7:41pm
Women who have had early breast cancer, along with their doctors, often worry that pregnancy could cause disease recurrence. But according to the results of a new study, that’s not the case.
Dr. El-Deiry on the Significance of Understanding Tumor Heterogeneity
June 3rd 2017, 5:26am
Wafik S. El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, William Wikoff Smith Chair in Cancer Research, American Cancer Society Research Professor, discusses the importance of understanding tumor heterogeneity an interview during the 2017 ASCO Annual Meeting.
Dr. Balar on Mature Clinical Results of KEYNOTE-052 in Urothelial Cancer
June 3rd 2017, 2:49am
Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the mature clinical trial results and biomarker findings of KEYNOTE-052, first-line pembrolizumab (Keytruda) in patients with cisplatin-ineligible advanced urothelial cancer, during the 2017 ASCO Annual Meeting.
Web-Based Therapy Helps Newly Diagnosed Patients Manage Stress
June 3rd 2017, 1:57am
Newly diagnosed patients with cancer experienced improvements in quality of life and lower levels of distress by participating in a web-based stress management program, according to results of a study presented at the 2017 ASCO Annual Meeting.
Testicular Cancer Survivors Face Health Risks From Low Testosterone
June 3rd 2017, 1:46am
Nearly 40% of testicular cancer survivors had low testosterone levels, leading to a greater likelihood of chronic health problem compared with survivors with normal testosterone levels, according to study findings released at the 2017 ASCO Annual Meeting.
CALM Psychotherapy Eases Depression and Distress in Patients With Advanced Cancer
June 3rd 2017, 1:34am
Advanced cancer exacts an overwhelming emotional toll, and a brief but novel psychological intervention involving individual therapy sessions delivered by trained therapists has been shown to alleviate patients’ distress and help them to manage the profound and practical problems that come with this diagnosis.
Late Effects of Childhood Cancers Dropping Along With Intensity of Treatments
June 3rd 2017, 12:33am
The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.
Single Dose of Radiation as Effective as 5-Day Course for Maintaining Mobility in Patients with Spinal Cord Compression
June 3rd 2017, 12:20am
Results from a large, phase III trial showed that a single radiation treatment relieves symptoms of spinal cord compression in patients with advanced cancer as effectively as a multifractional course of radiotherapy (RT)
Fear of Recurrence and Anxiety Lowered in Cancer Survivors After Psychological Intervention
June 3rd 2017, 12:09am
Psychological intervention can substantially lower fear of cancer recurrence in survivors, improving their quality of life, anxiety, and cancer-specific distress, according to a phase II randomized clinical trial presented at the 2017 ASCO Annual Meeting.
Ribociclib Benefit in Breast Cancer Sustained With Longer Follow-Up
June 2nd 2017, 9:06pm
Frontline treatment with ribociclib plus letrozole improved progression-free survival by 9.3 months compared with letrozole plus placebo for patients with postmenopausal HR-positive, HER2-negative advanced breast cancer.
Adjuvant Gefitinib Delays Recurrence in EGFR+ NSCLC
May 18th 2017, 1:13am
Adjuvant gefitinib reduced the risk of disease recurrence by 40% versus standard chemotherapy in patients with EGFR-positive non–small cell lung cancer, study reports.
Adopting Healthy Lifestyle Leads to Improved Overall Survival in Postsurgical Colon Cancer
May 18th 2017, 12:58am
Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.
HPV Vaccine Reduced High-Risk Oral Infections by Nearly 90%, but Poor Uptake Limits Impact
May 18th 2017, 12:44am
The efficacy of the human papillomavirus vaccine continues to be impressive, with newly reported findings showing that it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine; however, low vaccine uptake remains a concern.
Affordable Care Act Positively Affects Stage at Diagnosis
May 18th 2017, 12:35am
More Stage I cancers were diagnosed after the passage of the Affordable Care Act within five screenable disease types than were diagnosed before ACA implementation.
Eating Nuts After Colon Cancer Improves Survival and Lowers Recurrence Risk
May 18th 2017, 12:19am
Findings of a new prospective study suggest that eating tree nuts like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer.